RDATE:21082008

BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Wynn Resorts Ltd. (NASDAQ: WYNN), Genta Inc. (OTCBB: GNTA), Ormet Corp (OTC: ORMT), Extrudyne Inc (OTC: ETRUF). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.

Wynn Resorts Ltd. (NASDAQ: WYNN) together with its subsidiaries, engages in the development, ownership, and operation of destination casino resorts. The company owns and operates Wynn Las Vegas casino resort in Las Vegas, which includes 22 food and beverage outlets comprising 6 dining restaurants, 2 nightclubs, 1 spa and salon, 1 Ferrari and Maserati automobile dealership, wedding chapels, an 18-hole golf course, meeting space, and foot retail promenade featuring boutiques. As of December 31, 2007, Wynn Las Vegas casino resort featured 140 table games, 1 baccarat salon, private VIP gaming rooms, 1 poker room, 1,970 slot machines, and 1 race and sports book. It also owns Wynn Macau casino resort located in the Macau Special Administrative Region of the People's Republic of China. Wynn Macau casino resort featured 380 table games, 1,270 slot machines, 5 restaurants, 1 spa and salon, lounges, meeting facilities, and retail space featuring boutiques. The company was founded in 2002 and is based in Las Vegas, Nevada. With 111.83 million shares outstanding and 17.72 million shares declared short as of July 2008, there is a failure to deliver in shares of WYNN. According to quarterly data provided by the SEC, there were still 13,038 shares of WYNN that were failing-to-deliver as of September 27, 2007.

Genta Inc. (OTCBB: GNTA) operates as a biopharmaceutical company with a diversified product portfolio that is focused on delivering products for the treatment of patients with cancer. Its research portfolio consists of two programs, DNA/RNA Medicines and Small Molecules. The company's lead compound from its DNA/RNA Medicines program is Genasense (oblimersen sodium) injection that is designed to block the production of a protein, known as Bcl-2, which is a fundamental cause of the inherent resistance of cancer cells to anticancer treatments, such as chemotherapy, radiation, and monoclonal antibodies. Genta Incorporated is recruiting patients to the AGENDA Trial, a global Phase III trial of Genasense in patients with advanced melanoma. Its lead drug in its Small Molecule program is Ganite (gallium nitrate injection), which is marketed in the United States for the treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The company also develops G4544, an oral formulation of the active ingredient in Ganite, which entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. In addition, it is developing tesetaxel, an orally absorbed, semi-synthetic taxane that is in the same drug class as paclitaxel and docetaxel. The company was founded in 1988 and is based in Berkeley Heights, New Jersey. With 36.74 million shares outstanding and 2.54 million shares declared short as of July 2008, there is a failure to deliver in shares of GNTA. According to quarterly data provided by the SEC, there were still 239,625 shares of GNTA that were failing-to-deliver as of September 28, 2007.

Please enable Javascript

Ormet Corp (OTC: ORMT) through its subsidiaries, engages in the production and sale of aluminum and related products in the United States. It offers aluminum, and aluminum billet and ingot products. The company markets its aluminum ingots/sow to international traders and the U.S. based aluminum rolling mills for flat rolled products that are used for beverage cans, transportation, construction, appliance, and general industrial applications; and aluminum billet products to aluminum extrusion companies producing product primarily for the transportation and construction industries. Ormet Corporation was founded in 1956 and is based in Hannibal, Ohio. With 18.46 million shares outstanding and 300 shares declared short as of July 2008, there is a failure to deliver in shares of ORMT. According to quarterly data provided by the SEC, there were still 15,600 shares of ORMT that were failing-to-deliver as of August 1, 2007.

Extrudyne Inc (OTC: ETRUF) through its subsidiaries, engages in the exploration, development, and production of gold and diamond properties primarily in Africa. It holds interest in the Youga Gold project located in Burkina Faso, West Africa; and an 85% interest in the Agbaou Gold project comprising 939 square kilometers located in the northwest of Abidjan, West Africa. The company also owns interest in the Samira Hill Gold project, which is located in southwestern Niger; the Finkolo Gold and Keniebandi Gold projects located in Mali; the Ventersdorp Alluvial Diamond District; and the Blue Gum Diamond Deposit in South Africa. In addition, Etruscan Resources holds the Kamanjab project consisting of 6 permits covering approximately 5,000 square kilometers; and the Witvlei project comprising 5 contiguous permits with 4,000 square kilometers. Further, it has an option to acquire a 100% interest in the Bole-Bolgatanga Gold Belt covering 773 square kilometers in northern Ghana. Etruscan Resources also holds interests in the Ahafo, Bogoso-Prestea, Bibiani, Obotan, and Chirano deposits in the Sefwi Volcanic Belt and the Kumasi Sedimentary Basin, Ghana. The company is headquartered in Bedford, Canada. With 124.1 million shares outstanding and 13,800 shares declared short as of July 2008, there is a failure to deliver in shares of ETRUF. According to quarterly data provided by the SEC, there were still 44,300 shares of ETRUF that were failing-to-deliver as of September 20, 2007.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,100,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

Please enable Javascript

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.

BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.

BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

Please enable Javascript

CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net

((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com)).

This is a news service of Thomson Business Intelligence Service ©2006. This content is for your personal use only, subject to Terms and Conditions. No redistribution allowed.